The question sounds like trivia and is not. Whether a given GLP-1 is a peptide decides whether it arrives in a syringe or a bottle, whether it lives in a refrigerator, whether a meal ruins the dose, and whether roughly 1% or roughly 77% of it reaches the bloodstream. It is the single fact from which most of the practical differences in this drug class follow.
The answer is also genuinely split. The hormone is a peptide. Most of the drugs are peptides. One of them is a protein. One of them, newly approved, contains no peptide at all — and behaves completely differently as a result.
Which products are in the class at all is on which drugs are GLP-1s, and the four separate things the abbreviation now names are sorted on what is a GLP-1.
The hormone: yes, and the name says so
A peptide is a chain of amino acids — the same building blocks as a protein, in a chain short enough that convention calls it a peptide rather than a protein. The boundary is a matter of usage rather than chemistry, and sits loosely around fifty amino acids.
Glucagon-like peptide-1 carries the word in its name. Its main circulating form, GLP-1(7-36) amide, is a chain of 30 amino acids with the formula C149H226N40O45 and a molecular weight of 3,297.6 g/mol. For scale, that is a little over half the size of human insulin.
Being that small and that peptide-like is exactly why the hormone is useless as a medicine in its own right: enzymes take it apart in about 90 seconds to two minutes, a figure covered on natural GLP-1. Every drug below is an answer to that problem.
The drugs: a seventy-fold range inside one class
| What it is called | Molecular weight | What its label calls it structurally |
|---|---|---|
| Orforglipron (Foundayo) | 902.0 g/mol | small molecule, no peptide component |
| Native GLP-1(7-36) amide | 3,297.6 g/mol | the hormone, 30 amino acids |
| Liraglutide (Victoza, Saxenda) | 3,751.2 Da | acylated GLP-1 analogue, 97% homologous |
| Semaglutide (Ozempic, Wegovy, Rybelsus) | 4,113.58 g/mol | GLP-1 analogue, peptide backbone from yeast |
| Exenatide (Byetta) | 4,186.6 Da | 39-amino acid peptide amide |
| Tirzepatide (Mounjaro, Zepbound) | 4,813.53 Da | peptide based on the GIP sequence |
| Dulaglutide (Trulicity) | ~63,000 Da | fusion protein with an IgG4 Fc region |
Dulaglutide is roughly seventy times the mass of orforglipron, and both labels open their description with the same four words: a GLP-1 receptor agonist. The class is defined by where a molecule acts, not by what it is.
The three peptides, and what was done to them
Semaglutide, liraglutide and tirzepatide are all engineered against the same enemy — the enzyme DPP-4 and the kidneys — and the engineering is visible in the labels.
- Liraglutide is 97% homologous to native GLP-1, with arginine swapped for lysine at position 34, and a C16 palmitic acid attached through a glutamic acid spacer at position 26. Result: a plasma half-life of 13 hours against the hormone's 1.5 to 2 minutes.
- Semaglutide goes further. Position 26 carries a hydrophilic spacer and a C18 fatty di-acid, position 8 is modified specifically to resist DPP-4, and position 34 is altered so only one fatty acid attaches. The fatty acid binds albumin, which is what stretches the half-life to about a week.
- Tirzepatide is the odd one. It is unambiguously a peptide, with aminoisobutyric acid at positions 2 and 13, a C-terminal amide and a C20 diacid at Lys20 — but its backbone comes from GIP, a different incretin hormone. The best-known molecule in the weight-loss class is structurally a modified GIP peptide that happens to activate the GLP-1 receptor as well.
Exenatide is not modified human GLP-1 at all. Its label calls it a 39-amino acid peptide amide whose sequence "partially overlaps" that of human GLP-1 — a separate molecule that happens to fit the same receptor, and one that survives DPP-4 because it was never shaped for it.
Dulaglutide is a protein wearing the class name
Trulicity's description is worth reading slowly. Dulaglutide is a fusion protein: two identical chains linked by disulfide bonds, each consisting of a GLP-1 analogue sequence (90% homologous to the native hormone) covalently joined by a small peptide linker to the Fc portion of a modified human IgG4 antibody heavy chain. It is produced in Chinese hamster ovary cells rather than by peptide synthesis or yeast fermentation.
The antibody fragment is not decoration. It is the protraction strategy — the thing that makes a once-weekly injection possible — chosen instead of the fatty acid route Novo Nordisk took. Two manufacturers solved the same 90-second problem in two different ways, and the results differ seventeen-fold in mass.
The molecule that ends the pattern
Orforglipron, approved as Foundayo on a label effective 2026-07-29, is a GLP-1 receptor agonist that is not a peptide.
Its formula is C48H47F2N10O5 with half a calcium ion, and its chemical name is a catalogue of ring systems — indazole, imidazole, pyrazolo[4,3-c]pyridine, oxadiazole, indole. It is the kind of molecule a medicinal chemist builds, not one a ribosome makes. Its label's mechanism section is nevertheless indistinguishable in substance from the others: it binds to and activates the human GLP-1 receptor, and GLP-1 receptors are present in brain regions that regulate appetite.
What changes is everything downstream of the chemistry.
| Oral semaglutide (peptide) | Orforglipron (non-peptide) | |
|---|---|---|
| Absolute oral bioavailability | 0.4% to 1% (1% to 2% for the Ozempic tablet strengths) | 77% |
| Food | empty stomach, plain water, 30-minute wait | with or without food |
| Absorption enhancer | SNAC, required | none |
| Storage | room temperature bottle | room temperature, 20–25°C |
| Injectable siblings | refrigerated at 2–8°C | none |
A peptide taken by mouth loses 99% of itself to the digestive tract and needs a carrier molecule and a daily ritual to deliver the remaining fraction. A small molecule designed for the same receptor simply gets absorbed. That is the entire practical content of the question "is it a peptide", and it is why the answer is worth pinning down for any particular product. The two-route comparison for semaglutide is on GLP-1 pill vs injection; the injectable hardware is on GLP-1 injections explained.
One regulatory consequence worth noting
Foundayo still carries the class boxed warning about thyroid C-cell tumours, and the reasoning inside it is unusual. The warning states that orforglipron is not pharmacologically active in rats or mice and did not produce tumours in rodents — and then keeps the warning anyway, because the rodent effect is considered GLP-1 receptor-dependent, orforglipron is active at the human receptor, and the human relevance has not been determined.
So the drug carries a warning derived from an animal finding that could not be reproduced in it, because the animals it would have been tested in do not respond to it. Whether that is caution or an artefact of how class labelling works is not something a label answers. What it is safe to report is the distinction: the warning follows the receptor, not the chemistry. The class's safety documents are compared on is GLP-1 safe.
What this does not establish
- Being a peptide says nothing about whether a drug works. The mass table above contains the most and least effective products in the class in no particular order, and efficacy is a trial question, covered on GLP-1 before and after.
- The peptide-versus-protein line is a convention. Dulaglutide is called a fusion protein by its own label; nothing would break if it were called a very large peptide conjugate.
- Nothing here concerns unapproved peptides. The word covers approved medicines and research compounds alike; what separates them is a label and a manufacturer, not chemistry. The compounded side is on compounded semaglutide.
- No part of this is advice about any product. Clinical choices belong with a prescriber, as our editorial standards set out.
How this page was built
Description and clinical pharmacology sections were read from nine current FDA labels on DailyMed on 2026-09-18, each with its effective date recorded: Foundayo (2026-07-29), Ozempic injection (2026-06-01), oral semaglutide covering Ozempic and Rybelsus tablets (2026-01-30), Wegovy (2026-06-18), Mounjaro (2026-08-27), Zepbound (2026-08-28), Trulicity (2026-06-16), Byetta (2025-09-02) and Saxenda (2026-02-25). Molecular formulae and weights are quoted from those labels. The native hormone's formula and weight are from PubChem CID 16133831, read the same day. The insulin comparison uses human insulin's conventional molecular weight of 5,808 daltons.